Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma

Martin Hoyle, Colin Green, Jo Thompson-Coon, Zulian Liu, Karen Welch, Tiffany Moxham, Ken Stein

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences